YUNGJIN PHARM. CO. LTD (003520) Stock Price & Analysis

003520 Stock Chart & Stats

₩931.00₩0.00(0.00%)

At close: Oct 30 3:30 PM GMT+9

Day’s Range: KRW 907.00 - KRW 939.00
52-Week Range: KRW 907.00 - KRW 2,320.00
Previous Close: KRW 931.00
Volume: N/A
Average Volume (3M): 255.69K
Market Cap: KRW 170.27B
Enterprise Value: KRW 291.12B
Total Cash (Recent Filing): KRW 3.59B
Total Debt (Recent Filing): KRW 77.24B
Price to Earnings (P/E): ―
Beta: 0.13
Next Earnings: Nov 18, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Established Pharmaceutical Business

Yungjin Pharm has an established operating model spanning pharmaceutical research, development, manufacturing, and commercialization. Its prescription-drug focus and regulated domestic distribution channels provide an enduring platform for serving healthcare demand and supporting product continuity.

Relatively Stable Gross Margin

The relatively stable gross-margin range indicates that the company has maintained a broadly consistent level of value capture on products despite volatile operating results. This provides a foundation for recovery if revenue and operating execution improve, although it does not yet ensure profitability.

Balance Sheet Not Distressed

The balance sheet is described as mixed but not distressed, with sizable equity relative to assets and a reduction in total debt in the latest period. That position gives Yungjin Pharm some financial resilience while it works to restore profitability and cash generation.

Bears Say

Sharp Revenue Decline And Renewed Losses

The sharp TTM revenue contraction and return to operating and net losses show that earnings remain unstable rather than following a dependable recovery path. Continued weakness could reduce reinvestment capacity, impair operating leverage, and make future performance highly dependent on a revenue rebound.

Weak And Volatile Cash Generation

Negative TTM operating and free cash flow indicates that reported operations are not currently funding the business reliably. Persistent volatility can increase funding needs, limit reinvestment flexibility, and make liquidity more sensitive to any prolonged weakness in operating performance.

Material Legal Claim

The damages claim represents a potentially material exposure relative to Yungjin Pharm’s equity capital. Although the company plans to appoint counsel and respond actively, an adverse outcome could consume financial resources, weaken capital flexibility, and add uncertainty to already inconsistent results.

YUNGJIN PHARM. CO. LTD News

Yungjin Pharm Faces 9 Billion KRW Damage Claim in Seoul Court

YUNGJIN PHARM. CO. LTD ( ($KR:003520) ) has issued an announcement. Yungjin Pharm. Co. Ltd has disclosed that it has been sued by Lipobiolab in the Seoul Central District Court,

2M ago

YUNGJIN Pharm Reports Clean Intra-Group Dealings in KT&G Quarterly Disclosure

YUNGJIN PHARM. CO. LTD ( ($KR:003520) ) has provided an update. YUNGJIN PHARM. CO. LTD reported its quarterly disclosure on the status of the KT&G large business group, noting that

2M ago

003520 FAQ

What was YUNGJIN PHARM. CO. LTD’s price range in the past 12 months?

YUNGJIN PHARM. CO. LTD lowest stock price was ₩907.00 and its highest was ₩2320.00 in the past 12 months.

What is YUNGJIN PHARM. CO. LTD’s market cap?

YUNGJIN PHARM. CO. LTD’s market cap is ₩170.27B.

When is YUNGJIN PHARM. CO. LTD’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were YUNGJIN PHARM. CO. LTD’s earnings last quarter?

YUNGJIN PHARM. CO. LTD released its earnings results on Aug 14, 2026. The company reported -₩13.293 earnings per share for the quarter.

Is YUNGJIN PHARM. CO. LTD overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does YUNGJIN PHARM. CO. LTD pay dividends?

YUNGJIN PHARM. CO. LTD does not currently pay dividends.

What is YUNGJIN PHARM. CO. LTD’s EPS estimate?

YUNGJIN PHARM. CO. LTD’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does YUNGJIN PHARM. CO. LTD have?

YUNGJIN PHARM. CO. LTD has 182,892,730 shares outstanding.

What happened to YUNGJIN PHARM. CO. LTD’s price movement after its last earnings report?

YUNGJIN PHARM. CO. LTD reported an EPS of -₩13.293 in its last earnings report. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of YUNGJIN PHARM. CO. LTD?

Currently, no hedge funds are holding shares in KR:003520

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description